From pre-analytical phase to genetic analysis
Join us at 28th Congress of the European Society of Pathology from 25–29 September 2016, in the Kölnmesse in Cologne, Germany
Thermo Fisher Scientific provides solutions for histopathology and molecular pathology laboratories incl. all tools, instrumentation, and reagents to process tissue as well as liquid biopsy samples and analyse them to reveal the insights at genetic level.
Visit booth #1 to hear the latest in tissue processing and next generation sequencing for cancer research and diagnostics.
Meet us at the Thermo Fisher Scientific booth #1
Next generation sequencing workflows in oncology
- Solutions for liquid biopsy research
- Expanding family of Oncomine™ assays
- Our concept of Universal Companion Diagnostics test—coming soon
Ion Torrent next generation sequencing platforms
- Ion S5™ and Ion S5™ XL systems The Ion S5 XL next generation
sequencing system enables a simple targeted sequencing
workflow for your lab with reliable performance
and industry-leading speed
- Ion PGM™ Dx Instrument System* Designed to deliver the speed and simplicity of the Ion Torrent™ platform, combined with key workflow advantages designed specifically for regulated laboratory
environments and in vitro diagnostic applications
- Tissue processing platforms A complete line of Thermo Scientific™ anatomical pathology equipment and consumables
Join the symposium: Ion Torrent and Oncomine NGS solutions for clinical cancer biomarker research and diagnostics
Date: Tuesday, 27th September 2016
Venue: ECP 2016, Congress-Saal 3
Chair: Pr Philippe Gaulard, Département de Pathologie & Inserm U955 Hôpital Henri Mondor, Créteil
Part I. Next generation sequencing in clinical research
Experience with the complete Oncomine™ workflow including the reporting solution for clinical research
Peter Wild, Institute of Surgical Pathology, University Hospital Zurich
Validation of new NGS assay for BRCA 1 and 2 testing on FFPE tissue samples in clinical research
Markus Möbs, Institute of Pathology, Charité—Universitätsmedizin Berlin.
Part II. Next generation sequencing in routine oncology patient testing
NGS for detection of ALK rearrangements—comparison with IHC and FISH
Anne McLeer, Molecular Pathology Lab, Grenoble University Hospital Molecular Genetics Platform
Standardisation of NGS workflow for routine diagnostic use and developing of a model of reporting NGS diagnostics test for colon cancer
Elena Guerini Rocco, Histopathology and Molecular Diagnostics Unit, Division of Pathology, European Institute of Oncology
Part III: Moving ahead
Introducing the liquid biopsy applications for oncology research and Oncomine™ Universal Dx test for routine patient testing and therapy selection
Mark Aitkenhead, Thermo Fisher Scientific
NGS—driving revolution in cancer diagnostics and treatment management
Professor Massimo Barberis, Director of the Clinic Unit of Histopathology and Molecular Diagnostics European Institute of Oncology (IEO), Milan, Italy, and Professor Ian Cree, Molecular Pathologist at University Hospitals Coventry and Warwickshire, UK discuss their experiences with Next Generation Sequencing (NGS) and share their opinions about the technology’s potential for more widespread adoption in clinical settings.
Read the article in the June 2016 issue of the Pathologist journal.
For Research Use Only. Not for use in diagnostic procedures.
* For In Vitro Diagnostic Use. Available in the US and selected countries globally. Torrent Suite Assay Development Software is For Research Use Only, and not for use in diagnostic procedures.